A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 13vPnC + TIV in Pneumococcal Infections, sponsored by Pfizer. Completed. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-17.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 6th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 5th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2007.
This study's enrollment of 1,185 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 3, and was the 15th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation of the lungs). As trivalent influenza vaccine (TIV) is frequently given to adults, it is important to show that both vaccines can safely be given together without affecting the immune response (body's ability to protect against disease).
Inclusion Criteria:
Biological: 13-valent pneumococcal conjugate vaccine
Biological: 13vPnC + TIV
Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)
Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.
Time frame: Baseline and 1 month after TIV vaccination
13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)
IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Time frame: 1 month after 13vPnC vaccination
Percentage of Participants With Pre-specified Local Reactions
Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (\> 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).
Time frame: Days 1 through 14 after 13vPnC vaccination
Percentage of Participants With Pre-specified Systemic Events
Systemic events (Any fever \>= 38 degrees Celsius \[C\]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.
Time frame: Days 1 through 14 after 13vPnC vaccination
| Milestone | 13vPnC+TIV Followed by Placebo 1 Month Later | Placebo+TIV Followed by 13vPnC 1 Month Later |
|---|---|---|
| Started | 580 | 580 |
| Vaccinated dose 1 | 577 | 575 |
| Vaccinated dose 2 | 560 | 558 |
| Completed | 556 | 557 |
| Not completed | 24 | 23 |
| Withdrew: Subject request | 12 | 11 |
| Withdrew: Protocol violation | 7 | 8 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Failed to return | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.
| Percentage of participants | 13vPnC+TIV | Placebo+TIV |
|---|---|---|
| Influenza virus subtype: A/H1N1 | 80.3 (76.7 to 83.5) | 78.6 (74.9 to 81.9) |
| Influenza virus subtype: A/H3N2 | 58.0 (53.7 to 62.2) | 62.6 (58.4 to 66.6) |
| Influenza virus subtype: B | 52.2 (47.9 to 56.4) | 54.0 (49.7 to 58.3) |
IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
| mcg/mL | 13vPnC+TIV | 13vPnC |
|---|---|---|
| Serotype 1 | 2.52 (2.07 to 3.06) | 3.20 (2.61 to 3.91) |
| Serotype 3 | 1.08 (0.94 to 1.24) | 1.15 (1.01 to 1.30) |
| Serotype 4 | 2.15 (1.79 to 2.60) | 3.24 (2.65 to 3.96) |
| Serotype 5 | 4.74 (4.08 to 5.50) | 6.90 (5.87 to 8.11) |
| Serotype 6A | 4.61 (4.00 to 5.31) | 6.10 (5.13 to 7.24) |
| Serotype 6B | 6.24 (5.27 to 7.39) | 6.43 (5.33 to 7.76) |
| Serotype 7F | 7.63 (6.50 to 8.96) | 9.04 (7.58 to 10.79) |
| Serotype 9V | 4.97 (4.19 to 5.91) | 6.21 (5.27 to 7.33) |
| Serotype 14 | 8.95 (7.33 to 10.95) | 12.44 (9.94 to 15.57) |
| Serotype 18C | 8.88 (7.55 to 10.45) | 11.07 (9.40 to 13.04) |
| Serotype 19A | 11.93 (10.23 to 13.92) | 17.10 (14.54 to 20.10) |
| Serotype 19F | 4.78 (4.00 to 5.71) | 7.39 (6.02 to 9.08) |
| Serotype 23F | 5.82 (4.74 to 7.14) | 6.11 (4.97 to 7.50) |
Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (\> 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).
| percentage of participants | 13vPnC+TIV | 13vPnC |
|---|---|---|
| Redness: Any (n= 440, 432) | 16.6 (-0.4 to 9.0) | 12.3 (-0.4 to 9.0) |
| Redness: Mild (n= 438, 432) | 14.4 (0.3 to 9.1) | 9.7 (0.3 to 9.1) |
| Redness: Moderate (n= 433, 424) | 6.0 (-3.4 to 3.1) | 6.1 (-3.4 to 3.1) |
| Redness: Severe (n= 429, 420) | 0.7 (-1.8 to 1.2) | 1.0 (-1.8 to 1.2) |
| Swelling: Any (n= 441, 431) | 13.8 (-0.7 to 8.0) | 10.2 (-0.7 to 8.0) |
| Swelling: Mild (n= 440, 430) | 11.8 (-0.3 to 7.7) | 8.1 (-0.3 to 7.7) |
| Swelling: Moderate (n= 432, 423) | 4.2 (-3.7 to 2.1) | 5.0 (-3.7 to 2.1) |
| Swelling: Severe (n= 428, 420) | 0.2 (-0.7 to 1.3) | 0.0 (-0.7 to 1.3) |
| Pain: Any (n= 480, 470) | 40.0 (-9.7 to 3.0) | 43.4 (-9.7 to 3.0) |
| Pain: Mild (n= 470, 462) | 34.3 (-9.8 to 2.6) | 37.9 (-9.8 to 2.6) |
| Pain: Moderate (n= 447, 442) | 14.8 (-9.9 to 0.1) | 19.7 (-9.9 to 0.1) |
| Pain: Severe (n= 429, 421) | 1.4 (-3.4 to 0.8) | 2.6 (-3.4 to 0.8) |
| Limitation of arm movement: Any (n= 445, 432) | 13.9 (-5.6 to 3.8) | 14.8 (-5.6 to 3.8) |
| Limitation of arm movement: Mild (n= 444, 432) | 13.1 (-4.9 to 4.2) | 13.4 (-4.9 to 4.2) |
| Limitation of arm movement:Moderate (n= 430, 420) | 1.4 (-1.2 to 2.2) | 1.0 (-1.2 to 2.2) |
| Limitation of arm movement: Severe (n= 429, 420) | 1.9 (-1.4 to 2.4) | 1.4 (-1.4 to 2.4) |
| Any local reaction (n= 488, 470) | 46.9 (-6.0 to 6.7) | 46.6 (-6.0 to 6.7) |
Systemic events (Any fever \>= 38 degrees Celsius \[C\]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.
| Percentage of participants | 13vPnC+TIV | 13vPnC |
|---|---|---|
| Fever >=38 degreesC but <38.5 degreesC (n=434,423) | 3.0 (-2.5 to 2.3) | 3.1 (-2.5 to 2.3) |
| Fever >=38.5 degreesC but <39 degreesC (n=430,421) | 1.4 (-1.2 to 2.2) | 1.0 (-1.2 to 2.2) |
| Fever >=39degreesC but <=40.0degreesC (n=428,420) | 0.0 (-0.9 to 0.9) | 0.0 (-0.9 to 0.9) |
| Fever >40.0 degrees C (n= 429, 422) | 1.4 (-0.8 to 2.4) | 0.7 (-0.8 to 2.4) |
| Fatigue (n= 476, 456) | 37.4 (2.8 to 14.9) | 28.5 (2.8 to 14.9) |
| Headache (n= 472, 449) | 32.6 (2.1 to 13.8) | 24.7 (2.1 to 13.8) |
| Chills (n= 443, 429) | 13.8 (0.4 to 9.0) | 9.1 (0.4 to 9.0) |
| Rash (n= 433, 427) | 6.9 (-3.3 to 3.6) | 6.8 (-3.3 to 3.6) |
| Vomiting (n= 432, 424) | 3.0 (-0.7 to 3.6) | 1.7 (-0.7 to 3.6) |
| Decreased appetite (n= 450, 434) | 16.9 (1.0 to 10.2) | 11.3 (1.0 to 10.2) |
| New muscle pain (n= 468, 448) | 26.9 (-2.2 to 9.1) | 23.4 (-2.2 to 9.1) |
| Any aggravated muscle pain (n= 454, 439) | 18.7 (-1.2 to 8.7) | 15.0 (-1.2 to 8.7) |
| New joint pain (n= 452, 435) | 16.2 (0.1 to 9.2) | 11.5 (0.1 to 9.2) |
| Any aggravated joint pain (n= 452, 428) | 15.7 (2.7 to 11.4) | 8.6 (2.7 to 11.4) |
| Any systemic event (n= 510, 488) | 60.2 (5.4 to 17.8) | 48.6 (5.4 to 17.8) |
Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of a subset of participants using a microcolony OPA (mcOPA) assay.
| Geometric mean titers | 13vPnC+TIV | 13vPnC |
|---|---|---|
| Serotype 1 (n= 256, 255) | 88 (71.1 to 108.3) | 95 (76.8 to 117.9) |
| Serotype 3 (n= 235, 237) | 46 (37.9 to 56.1) | 51 (41.7 to 61.7) |
| Serotype 4 (n= 247, 245) | 997 (766.3 to 1296.0) | 1486 (1174.7 to 1879.8) |
| Serotype 5 (n= 245, 234) | 124 (97.3 to 158.8) | 112 (85.1 to 146.3) |
| Serotype 6A (n= 250, 252) | 1220 (950.6 to 1566.7) | 1597 (1256.4 to 2030.3) |
| Serotype 6B (n= 259, 248) | 1564 (1239.4 to 1973.9) | 2017 (1564.8 to 2599.9) |
| Serotype 7F (n= 246, 248) | 607 (444.2 to 828.8) | 835 (619.9 to 1123.9) |
| Serotype 9V (n= 247, 242) | 477 (348.5 to 652.7) | 723 (528.1 to 988.9) |
| Serotype 14 (n= 247, 236) | 975 (781.6 to 1215.5) | 1088 (858.4 to 1379.1) |
| Serotype 18C (n= 250, 244) | 1158 (909.5 to 1475.1) | 1415 (1122.0 to 1785.8) |
| Serotype 19A (n= 251, 247) | 445 (365.1 to 542.1) | 539 (427.8 to 679.7) |
| Serotype 19F (n= 247, 242) | 378 (295.8 to 483.8) | 467 (360.7 to 605.1) |
| Serotype 23F (n= 252, 242) | 245 (180.2 to 332.4) | 295 (217.9 to 400.8) |
Collected over AEs/SAEs recorded from signing of informed consent form to completion of study (Visit 3).Participants recorded in the e-diary their local reactions,systemic events & use of antipyretic & pain medication (Day 1-Day 14 after study vaccine administration).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC+TIV | — | 4/576 (0.7%) | 307/576 (53.3%) |
| Placebo | — | 8/559 (1.4%) | 194/559 (34.7%) |
| Placebo+TIV | — | 0/575 (0%) | 256/575 (44.5%) |
| 13vPnC | — | 5/558 (0.9%) | 237/558 (42.5%) |
| Event | 13vPnC+TIV | Placebo | Placebo+TIV | 13vPnC |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/576 | 2/559 | 0/575 | 1/558 |
| Duodenal ulcer perforationGastrointestinal disorders | 0/576 | 0/559 | 0/575 | 1/558 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/576 | 0/559 | 0/575 | 1/558 |
| PeritonitisGastrointestinal disorders | 0/576 | 0/559 | 0/575 | 1/558 |
| Sternal fractureInjury, poisoning and procedural complications | 0/576 | 0/559 | 0/575 | 1/558 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/576 | 0/559 | 0/575 | 1/558 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/576 | 0/559 | 0/575 | 1/558 |
| Angina pectorisCardiac disorders | 1/576 | 1/559 | 0/575 | 0/558 |
| Atrial fibrillationCardiac disorders | 0/576 | 1/559 | 0/575 | 0/558 |
| CholecystitisHepatobiliary disorders | 0/576 | 1/559 | 0/575 | 0/558 |
| Event | 13vPnC+TIV | Placebo | Placebo+TIV | 13vPnC |
|---|---|---|---|---|
| Pain (any)Skin and subcutaneous tissue disorders | 192/480 | 40/411 | 45/445 | 204/470 |
| Pain (mild)Skin and subcutaneous tissue disorders | 161/470 | 33/408 | 40/443 | 175/462 |
| FatigueGeneral disorders | 178/476 | 120/434 | 154/483 | 130/456 |
| HeadacheGeneral disorders | 154/472 | 114/436 | 139/468 | 111/449 |
| New muscle painGeneral disorders | 126/468 | 47/413 | 76/456 | 105/448 |
| Pain (moderate)Skin and subcutaneous tissue disorders | 66/447 | 10/397 | 14/437 | 87/442 |
| Any aggravated muscle painGeneral disorders | 85/454 | 44/410 | 63/449 | 66/439 |
| Decreased appetiteGeneral disorders | 76/450 | 58/415 | 66/452 | 49/434 |
| Redness (any)Skin and subcutaneous tissue disorders | 73/440 | 6/393 | 11/433 | 53/432 |
| New joint painGeneral disorders | 73/452 | 45/408 | 59/451 | 50/435 |
| Age Continuous(years) | 13vPnC+TIV Followed by Placebo 1 Month Later | Placebo+TIV Followed by 13vPnC 1 Month Later | Total |
|---|---|---|---|
| Mean | 72.1 ± 5.6 | 72.1 ± 5.5 | 72.1 ± 5.5 |
| Sex: Female, Male(Participants) | 13vPnC+TIV Followed by Placebo 1 Month Later | Placebo+TIV Followed by 13vPnC 1 Month Later | Total |
|---|---|---|---|
| Female | 289 | 290 | 579 |
| Male | 287 | 285 | 572 |
No study locations are listed for this record.
The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 4 years after primary completion. A results delay was requested in Jan 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine